NCT05131971 is a Phase 1 clinical trial of GSK3888130B in Multiple Sclerosis, sponsored by GlaxoSmithKline.

Who is sponsoring NCT05131971?

NCT05131971 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT05131971?

Interventions in NCT05131971: GSK3888130B, Placebo.

What condition does NCT05131971 study?

NCT05131971 studies Multiple Sclerosis, Colitis, Ulcerative.

Is NCT05131971 still recruiting?

NCT05131971 is currently completed. Last updated 26 March 2025.

Are results published for NCT05131971?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-03-26 · How we verify

NCT05131971

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants

Completed Phase 1 Results posted Last updated 26 March 2025

What this trial tests

Phase 1 trial testing GSK3888130B in Multiple Sclerosis in 54 participants. Completed in 12 October 2023.

Timeline

1 November 2021

Primary endpoint
12 October 2023

12 October 2023

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	treatment
Enrollment	54
Start date	1 November 2021
Primary completion	12 October 2023
Estimated completion	12 October 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

GSK3888130B — full drug profile →
Placebo

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →
Colitis, Ulcerative — all drugs for Colitis, Ulcerative →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 55, any sex, with Multiple Sclerosis or Colitis, Ulcerative. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Primary · Up to 160 days

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any serious adverse event that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment.

AEs

Group	Value	95% CI
Placebo	8
GSK3888130B Dose Level 1 IV	3
GSK3888130B Dose Level 2 IV	2
GSK3888130B Dose Level 3 SC	6
GSK3888130B Dose Level 4 IV	2
GSK3888130B Dose Level 5 SC	4
GSK3888130B Dose Level 6 IV	8
GSK3888130B Dose Level 7 IV	5

SAEs

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	0

Number of Participants With Clinically Significant Changes in Hematology Results Primary · Up to 85 days

Blood samples were collected for analysis of following hematology parameters: Basophils, Eosinophils, Hematocrit, Hemoglobin (Hg), Lymphocytes, Mean corpuscular Hg, Mean corpuscular volume, Monocytes, Platelet count, Red blood cell count, Reticulocytes, Total Neutrophils, and White blood cells count (WBC). Number of participants with clinically significant changes in hematology were reported. Clinical significance was determined by the investigator.

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	0

Number of Participants With Worst-case Cluster of Differentiation (CD) 4+ T Cell Counts Results by Maximum Grade Increase Post-Baseline Relative to Baseline Primary · Baseline (Day 1) and up to 85 days

Blood samples were collected for the analysis of CD4+ T Cell Counts. The CD4+ T Cell Counts were graded according to National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE). Grade 0: Above 0.5\*10\^9 cells/Liter (L), Grade 1: \<0.5 to 0.2\*10\^9 cells/L, Grade 2: \<0.2 to 0.05\*10\^9 cells/L, Grade 3: Below 0.05\*10\^9 cells/L. Baseline was defined as the latest pre-dose assessment. An increase was defined as an increase in grade relative to Baseline grade. Any worst-case post Baseline increase to Grade 1, Grade 2 and Grade 3 are presented.

Increase to Grade 1

Group	Value	95% CI
Placebo	4
GSK3888130B Dose Level 1 IV	1
GSK3888130B Dose Level 2 IV	1
GSK3888130B Dose Level 3 SC	1
GSK3888130B Dose Level 4 IV	1
GSK3888130B Dose Level 5 SC	3
GSK3888130B Dose Level 6 IV	5
GSK3888130B Dose Level 7 IV	4

Increase to Grade 2

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	0

Increase to Grade 3

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	0

Number of Participants With Worst-case Creatinine Results by Maximum Grade Increase Post-Baseline Relative to Baseline Primary · Baseline (Day 1) and up to 85 days

Blood samples were collected for the analysis of Creatinine. Creatinine was graded according to the NCI-CTCAE. Grade 0: \<1.5\* Baseline, or increase from Baseline \<26 micromoles per liter (umol/L), Grade 1: 1.5 to 1.9\* Baseline, or increase from Baseline \>=26 umol/L, Grade 2: 2.0 to 2.9\* Baseline, Grade 3: \>=3.0\* Baseline, or \>=354 umol/L. Baseline was defined as the latest pre-dose assessment. An increase was defined as an increase in grade relative to Baseline grade. Any worst-case post Baseline increase to Grade 1, Grade 2 and Grade 3 are presented.

Increase to Grade 1

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	1
GSK3888130B Dose Level 7 IV	0

Increase to Grade 2

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	0

Increase to Grade 3

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	0

Number of Participants With Clinically Significant Changes in Clinical Chemistry Results Primary · Up to 85 days

Blood samples were collected for analysis of following clinical chemistry parameters: Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Calcium, Total and Direct bilirubin, Glucose, Potassium, Sodium, Total protein, Lactate dehydrogenase, Haptoglobins and Urea. Number of participants with clinically significant changes in clinical chemistry were reported. Clinical significance was determined by the investigator.

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	0

Number of Participants With Worst-case Any Increase in Urinalysis Results Post-Baseline Relative to Baseline Primary · Baseline (Day 1) and up to 85 days

Urine samples were collected for analysis of Specific gravity, potential of hydrogen (pH), glucose, protein, erythrocytes, ketones, bilirubin, urobilinogen, nitrite, and leukocyte in urine by dipstick. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters can be read as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Any increase means any increase to trace, 1+, 2+ or 3+ post-Baseline relative to Baseline. Baseline was defined as the latest pre-dose assessment. Number of participants with worst-case any incr

Bilirubin

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	0

Erythrocytes

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	1
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	2
GSK3888130B Dose Level 6 IV	1
GSK3888130B Dose Level 7 IV	0

Glucose

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	1
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	0

Ketones

Group	Value	95% CI
Placebo	1
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	1

Leukocytes

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	0

Nitrite

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	1
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	0

Protein

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	1
GSK3888130B Dose Level 7 IV	2

Specific Gravity

Group	Value	95% CI
Placebo	8
GSK3888130B Dose Level 1 IV	3
GSK3888130B Dose Level 2 IV	2
GSK3888130B Dose Level 3 SC	4
GSK3888130B Dose Level 4 IV	5
GSK3888130B Dose Level 5 SC	6
GSK3888130B Dose Level 6 IV	5
GSK3888130B Dose Level 7 IV	6

Number of Participants With Clinically Significant Changes in Vital Sign Results Primary · Up to 85 days

Vital signs included systolic and diastolic blood pressure, pulse and respiratory rate and were measured with the participant in semi-supine position after 5 minutes rest. Temperature was also measured as a vital sign but did not require positioning or rest prior to measuring. Clinical significance was determined by the investigator.

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	0

Number of Participants With Positive Cytomegalovirus (CMV) Deoxyribonucleic Acid (DNA) and Varicella Zoster Virus (VZV) DNA Primary · Baseline (Day 1), Day 15 and Day 85

VZV-Nucleic acid from blood samples were extracted using the QIASymphony SP followed by TaqMan real time polymerase chain reaction (PCR) for amplification and detection. Murine cytomegalovirus (mCMV) was used as an internal control (IC) and was introduced during the extraction process. CMV-Nucleic acid was extracted using the QIASymphony SP/AS followed by automated set up of Artus real time PCR using the Rotor-Gene Q for amplification and detection. Baseline was defined as the latest pre-dose assessment. Number of participants with Positive CMV DNA and VZV DNA has been presented.

Cytomegalovirus DNA, Baseline (Day 1)

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	0

Cytomegalovirus DNA, Day 15

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	0

Cytomegalovirus DNA, Day 85

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	0

Varicella Zoster Virus DNA, Baseline (Day 1)

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	0

Varicella Zoster Virus DNA, Day 15

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	0

Varicella Zoster Virus DNA, Day 85

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	0

Number of Participants With Positive Epstein-Barr Virus (EBV) DNA Primary · Baseline (Day 1), Day 15 and Day 85

EBV DNA was assessed and qualitative data has been presented. Data has been categorized into 'Positive \>=LLQ' and 'Positive \< LLQ'. LLQ is lower limit of quantification. Participants who had EBV DNA values \>=LLQ were categorized as 'Positive \>=LLQ'. This represents a positive result that is above the assay limit of quantification. Participants who had EBV DNA values \<LLQ were categorized as 'Positive \<LLQ'. This represents a positive result that is below the assay limit of quantification. Baseline was defined as the latest pre-dose assessment.

Baseline (Day 1), Positive < LLQ

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	1
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	1
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	1

Baseline (Day 1), Positive >= LLQ

Group	Value	95% CI
Placebo	2
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	1
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	2

Day 15, Positive < LLQ

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	1
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	2
GSK3888130B Dose Level 7 IV	1

Day 15, Positive >= LLQ

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	1
GSK3888130B Dose Level 7 IV	0

Day 85, Positive < LLQ

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	0

Day 85, Positive >= LLQ

Group	Value	95% CI
Placebo	1
GSK3888130B Dose Level 1 IV	1
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	1
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	1

Number of Participants With Worst-case Post-Baseline Abnormal Electrocardiogram (ECG) Findings Primary · Up to 85 days

Twelve lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, and QT corrected interval. Abnormal findings were categorized as clinically significant (CS) and not clinically significant (NCS). Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with worst case post-Baseline abnormal ECG findings have been presented.

CLINICALLY SIGNIFICANT

Group	Value	95% CI
Placebo	0
GSK3888130B Dose Level 1 IV	0
GSK3888130B Dose Level 2 IV	0
GSK3888130B Dose Level 3 SC	0
GSK3888130B Dose Level 4 IV	0
GSK3888130B Dose Level 5 SC	0
GSK3888130B Dose Level 6 IV	0
GSK3888130B Dose Level 7 IV	0

NOT CLINICALLY SIGNIFICANT

Group	Value	95% CI
Placebo	12
GSK3888130B Dose Level 1 IV	1
GSK3888130B Dose Level 2 IV	2
GSK3888130B Dose Level 3 SC	6
GSK3888130B Dose Level 4 IV	4
GSK3888130B Dose Level 5 SC	6
GSK3888130B Dose Level 6 IV	7
GSK3888130B Dose Level 7 IV	5

Serum Concentrations of GSK3888130B for Dose Levels 1, 2 and 4 Intravenous Administration Secondary · Day 1: Pre-dose, 15 minutes, 30 minutes, 4, 8, 12, 24, 48 hours; Days 6, 8, 10, 15, 21, 29, 57, and 85

Blood samples were collected at indicated time points for measurement of serum concentrations of GSK3888130B following intravenous administration. Pharmacokinetic (PK) Population consisted of all participants in the Safety analysis set who had received an active study intervention and had at least 1 non-missing post dose PK assessment (Non-quantifiable \[NQ\] values were considered as non-missing values).

DAY 1 (Pre-dose)

Group	Value	95% CI
GSK3888130B Dose Level 1 IV	NA	NA – NA
GSK3888130B Dose Level 2 IV	NA	NA – NA
GSK3888130B Dose Level 4 IV	NA	NA – NA

DAY 1 (15 Minutes)

Group	Value	95% CI
GSK3888130B Dose Level 1 IV	363.2	196.7 – 670.9
GSK3888130B Dose Level 2 IV	2155.9	1003.0 – 4634.4
GSK3888130B Dose Level 4 IV	15901.1	13993.4 – 18069.0

DAY 1 (30 Minutes)

Group	Value	95% CI
GSK3888130B Dose Level 1 IV	893.1	504.7 – 1580.5
GSK3888130B Dose Level 2 IV	4717.5	3173.3 – 7013.1
GSK3888130B Dose Level 4 IV	35633.0	30628.5 – 41455.2

DAY 1 (4 Hours)

Group	Value	95% CI
GSK3888130B Dose Level 1 IV	761.4	677.2 – 856.1
GSK3888130B Dose Level 2 IV	4497.0	2542.8 – 7953.0
GSK3888130B Dose Level 4 IV	32762.8	28319.4 – 37903.3

DAY 1 (8 Hours)

Group	Value	95% CI
GSK3888130B Dose Level 1 IV	753.5	483.7 – 1173.8
GSK3888130B Dose Level 2 IV	3964.2	1974.7 – 7958.0
GSK3888130B Dose Level 4 IV	31180.8	27855.3 – 34903.4

DAY 1 (12 Hours)

Group	Value	95% CI
GSK3888130B Dose Level 1 IV	758.1	601.3 – 955.8
GSK3888130B Dose Level 2 IV	3599.9	2601.7 – 4981.2
GSK3888130B Dose Level 4 IV	29821.8	26986.2 – 32955.3

DAY 1 (24 Hours)

Group	Value	95% CI
GSK3888130B Dose Level 1 IV	720.8	558.6 – 930.0
GSK3888130B Dose Level 2 IV	3781.5	2095.7 – 6823.7
GSK3888130B Dose Level 4 IV	28096.6	26173.0 – 30161.6

DAY 1 (48 Hours)

Group	Value	95% CI
GSK3888130B Dose Level 1 IV	572.8	401.3 – 817.7
GSK3888130B Dose Level 2 IV	3184.0	2280.6 – 4445.1
GSK3888130B Dose Level 4 IV	23358.3	20418.2 – 26721.8

Serum Concentrations of GSK3888130B for Dose Levels 3 and 5 Subcutaneous Administration Secondary · Day 1: Pre-dose, 4, 8, 12, 24, 48 hours; Days 6, 8, 10, 15, 21, 29, 57, and 85

Blood samples were collected at indicated time points for measurement of serum concentrations of GSK3888130B following subcutaneous administration.

DAY 1 (Pre-dose)

Group	Value	95% CI
GSK3888130B Dose Level 3 SC	NA	NA – NA
GSK3888130B Dose Level 5 SC	NA	NA – NA

DAY 1 (4 Hours)

Group	Value	95% CI
GSK3888130B Dose Level 3 SC	NA	NA – NA
GSK3888130B Dose Level 5 SC	2540.4	1193.5 – 5407.6

DAY 1 (8 Hours)

Group	Value	95% CI
GSK3888130B Dose Level 3 SC	NA	NA – NA
GSK3888130B Dose Level 5 SC	5287.2	2659.9 – 10509.8

DAY 1 (12 Hours)

Group	Value	95% CI
GSK3888130B Dose Level 3 SC	NA	NA – NA
GSK3888130B Dose Level 5 SC	8236.8	4122.6 – 16456.5

DAY 1 (24 Hours)

Group	Value	95% CI
GSK3888130B Dose Level 3 SC	1284.2	795.2 – 2073.7
GSK3888130B Dose Level 5 SC	14161.9	7502.7 – 26731.7

DAY 1 (48 Hours)

Group	Value	95% CI
GSK3888130B Dose Level 3 SC	2297.0	1506.7 – 3501.9
GSK3888130B Dose Level 5 SC	23239.0	12191.4 – 44297.5

DAY 6

Group	Value	95% CI
GSK3888130B Dose Level 3 SC	3253.7	2339.4 – 4525.5
GSK3888130B Dose Level 5 SC	34612.8	25180.0 – 47579.2

DAY 8

Group	Value	95% CI
GSK3888130B Dose Level 3 SC	3327.1	2422.0 – 4570.5
GSK3888130B Dose Level 5 SC	34801.7	25828.6 – 46892.0

Adverse events — posted to ClinicalTrials.gov

Time frame: All-cause mortality, serious adverse events (SAEs) and common non-serious adverse events (non-SAEs) were collected up to 160 days. Reporting threshold: 3%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Placebo

Serious: 0/15 (0%)

Deaths: 0/15

GSK3888130B Dose Level 1 IV

Serious: 0/3 (0%)

Deaths: 0/3

GSK3888130B Dose Level 2 IV

Serious: 0/3 (0%)

Deaths: 0/3

GSK3888130B Dose Level 3 SC

Serious: 0/6 (0%)

Deaths: 0/6

GSK3888130B Dose Level 4 IV

Serious: 0/6 (0%)

Deaths: 0/6

GSK3888130B Dose Level 5 SC

Serious: 0/6 (0%)

Deaths: 0/6

GSK3888130B Dose Level 6 IV

Serious: 0/9 (0%)

Deaths: 0/9

GSK3888130B Dose Level 7 IV

Serious: 0/6 (0%)

Deaths: 0/6

Other adverse events (45 terms — click to expand)

Reaction	System	Placebo	GSK3888130B Dose Level 1 IV	GSK3888130B Dose Level 2 IV	GSK3888130B Dose Level 3 SC	GSK3888130B Dose Level 4 IV	GSK3888130B Dose Level 5 SC	GSK3888130B Dose Level 6 IV	GSK3888130B Dose Level 7 IV
COVID-19	Infections and infestations	—	—	—	—	—	—	—	—
Nasopharyngitis	Infections and infestations	—	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—	—
Hypertransaminasaemia	Hepatobiliary disorders	—	—	—	—	—	—	—	—
Influenza	Infections and infestations	—	—	—	—	—	—	—	—
Nasal congestion	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—
Dermatitis contact	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—
Ear pain	Ear and labyrinth disorders	—	—	—	—	—	—	—	—
Gastrooesophageal reflux disease	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Toothache	Gastrointestinal disorders	—	—	—	—	—	—	—	—
Catheter site pain	General disorders	—	—	—	—	—	—	—	—
Catheter site rash	General disorders	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—
Influenza like illness	General disorders	—	—	—	—	—	—	—	—
Injection site pruritus	General disorders	—	—	—	—	—	—	—	—
Malaise	General disorders	—	—	—	—	—	—	—	—
Swelling face	General disorders	—	—	—	—	—	—	—	—
Seasonal allergy	Immune system disorders	—	—	—	—	—	—	—	—
Acne pustular	Infections and infestations	—	—	—	—	—	—	—	—
Cellulitis	Infections and infestations	—	—	—	—	—	—	—	—
Infected cyst	Infections and infestations	—	—	—	—	—	—	—	—
Lower respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—
Oral herpes	Infections and infestations	—	—	—	—	—	—	—	—
Arthropod bite	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—
Contusion	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—
Ligament sprain	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—
Procedural pain	Injury, poisoning and procedural complications	—	—	—	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—	—	—	—
Blood creatine phosphokinase increased	Investigations	—	—	—	—	—	—	—	—
Blood pressure diastolic increased	Investigations	—	—	—	—	—	—	—	—
Blood pressure increased	Investigations	—	—	—	—	—	—	—	—
Haemoglobin decreased	Investigations	—	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—
Head discomfort	Nervous system disorders	—	—	—	—	—	—	—	—
Paraesthesia	Nervous system disorders	—	—	—	—	—	—	—	—

Data from ClinicalTrials.gov NCT05131971 adverse events section.

Sponsor's own description

This is a first time in human study designed to assess the safety, tolerability, pharmacokinetics and PD of GSK3888130B over a range of dose levels in healthy participants.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting γc family cytokines with biologics: current status and future prospects.
Bick F, Blanchetot C, Lambrecht BN, Schuijs MJ. · · 2025 · cited 5× · PMID 39967341 · DOI 10.1080/19420862.2025.2468312
Comparative Efficacy of Interleukin-7 and -15 Blockade in Alleviating Experimental Chronic Uveitis and Suppressing Pathogenic Memory CD4+ T Cells.
Zhu Q, Shayan M, Huckfeldt RM, Chen Y. · · 2025 · cited 2× · PMID 40323267 · DOI 10.1167/iovs.66.5.9

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05131971 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 26 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05131971.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT05131971

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other recruiting trials for Multiple Sclerosis

Other GlaxoSmithKline trials

Verify against primary sources